Chen Xiangjie, Cheng Jing, Gong Jianrui
Department of Emergency Medicine, The Fourth People's Hospital of Kunshan Kunshan 215331, Jiangsu Province, China.
Am J Transl Res. 2021 Aug 15;13(8):9348-9355. eCollection 2021.
This study was designed to analyze the clinical effectiveness of Deanxit (DEA) for treating chronic subjective dizziness (CSD).
A total of 110 CSD patients (all from a community survey) admitted to our hospital from August 2018 to August 2020 were recruited as the study cohort. Among them, 60 who underwent DEA treatment were placed in the research group (RG) and 50 who underwent basic treatment were placed in the control group (CG). The two groups' efficacy, their dizziness disability rating scale (DHI) scores, the improvement in their clinical symptoms (duration of dizziness, frequency of dizziness attacks), their anxiety and depression (i.e., their Hamilton Anxiety Scale (HAMA) scores) and their Hamilton Depression Scale (HAMD)) scores, their sleep quality and their quality of life (short form 36 (SF-36) health survey scores) were observed and compared.
Compared with the CG, the DHI scores, the dizziness durations, the number of dizziness attacks and the HAMA and HAMD scores in the RG were markedly lower than they were in the CG, and the sleep quality levels and SF-36 scores were higher than they were in the CG.
DEA treatment helps to improve the dizziness, anxiety, and quality of life of CSD patients.
本研究旨在分析黛力新（DEA）治疗慢性主观性头晕（CSD）的临床疗效。
选取2018年8月至2020年8月我院收治的110例CSD患者（均来自社区调查）作为研究队列。其中，60例接受DEA治疗的患者被纳入研究组（RG），50例接受基础治疗的患者被纳入对照组（CG）。观察并比较两组的疗效、头晕残障评定量表（DHI）得分、临床症状改善情况（头晕持续时间、头晕发作频率）、焦虑和抑郁情况（即汉密尔顿焦虑量表（HAMA）得分）以及汉密尔顿抑郁量表（HAMD）得分、睡眠质量和生活质量（36条目简明健康调查量表（SF-36）得分）。
与CG组相比，RG组的DHI得分、头晕持续时间、头晕发作次数以及HAMA和HAMD得分均显著低于CG组，睡眠质量水平和SF-36得分高于CG组。
DEA治疗有助于改善CSD患者的头晕、焦虑和生活质量。
